Early hepatocellular carcinoma (BCLC 0 and A): lines of therapy
5 standard-of-care settings across 1 lines and 1 biomarker subgroup. Rows come from the cancer page's standard of care; the grid places each on its line and subgroup.
| Line | All comers |
|---|---|
| Other settings | 5 |
Other settings
| Subgroup | Setting | Approach | Products and trials | Guideline | Evidence |
|---|---|---|---|---|---|
| All comers | Single tumour, preserved liver function | Hepatectomy, increasingly laparoscopic or robotic; ablation as an alternative for tumours up to 3 cm. | 40 | ||
| All comers | Within Milan criteria with cirrhosis or portal hypertension | Liver transplantation, with bridging ablation or chemoembolisation on the waiting list and downstaging for patients just outside the criteria. | 59 | ||
| All comers | Not suitable for surgery or ablation | Stereotactic body radiotherapy or radioembolisation. | 40 | ||
| All comers | After curative treatment | No proven adjuvant therapy (STORM and IMbrave050 negative in the end); antiviral therapy, alcohol abstinence and continued imaging surveillance. | 98 | ||
| All comers | Detection | Six-monthly ultrasound with alpha-fetoprotein in cirrhosis and chronic hepatitis B. | 40 |
Lines and subgroups are parsed from the setting text of each standard-of-care row and can misclassify an unusual phrasing; the row’s own setting is always shown. Guideline chips reflect the NCCN category and ESMO-MCBS grade recorded on the cancer page, checked on its stated date. Not medical advice.